VEGFA and hepatocellular carcinoma: However, a recent report revealed an increased risk of all-grade gastrointestinal hemorrhage due to the anti-VEGF effect associated with the use of sorafenib in patients with HCC, especially when the HCC was accompanied by underlying varices, thus affecting the architectural integrity of the endothelial cells of the microvasculature [26].